EPA New Chemicals data shows submitter-side delays hold up market entry
EPA's New Chemicals Program status pages show a familiar pattern: cases sitting in risk assessment, and cases waiting on the submitter to sign a consent order. The useful takeaway for companies is that regulatory delay is not always EPA's doing. Incomplete information, unresolved exposure data and slow internal order-signature workflows can add weeks or months to a launch. New-chemical approval is best run as a launch-readiness discipline, not a filing you hand off and wait on.
Published10 Sept 2026
EffectiveObservation from EPA New Chemicals Program status pages, September 2026. No fixed date — review time depends on submission completeness and internal order-signature turnaround.
Read the full analysis